# Gut Microbiome Testing Market

> Gut Microbiome Testing Market Research Report: Information by Product & Services (Instruments, Consumables and Services), By Application (16S rRNA Sequencing, Shotgun Metagenomics, Meta transcriptomics, Next Generation Sequencing, Others), By Sample Type (Stool (Fecal) Samples, Saliva Samples, Others), By Indication (Ulcerative Colitis, Irritable Bowel Syndrome (IBS), Chronic Diarrhea & Constipation, Type-2 Diabetes, Obesity, Rheumatoid Arthritis, Multiple Sclerosis, Parkinson’s Disease, Alzheimer’s Disease, Others)By End User (Hospitals, Diagnostic Laboratories, and Others), By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa) -Global Forecast to 2035.

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.9%
- **2024:** $ 914.2 Million
- **2025:** $ 986.42 Million
- **2035:** $ 2,104.4 Million
- **Key Players:** Companies such as Viome Life Sciences, Inc, Ombre, BaseClear B.v., AtlasBiolabs, Microba Life Sciences, Genova Diagnostics, Inc, Sun Genomics, Inc., BIOHM Health, Inc, Zymo Research Corporation, CosmosID, Inc. are some of the major participants in the global market.

**Report ID:** MRFR/Pharma/66565-CR · **Pages:** 130 · **Author:** Snehal Singh & Rahul Gotadki · **Last Updated:** July 02, 2026

**URL:** https://www.marketresearchfuture.com/reports/gut-microbiome-testing-market-68365

---

## Market Drivers

### Growth of Personalized Nutrition & Preventive Health

Personalized nutrition and preventive health are becoming the new trends and they are significantly pushing the gut microbiome testing market up. The traditional diet is being slowly replaced by the individual nutrition plan which takes into account the person's genetic makeup, lifestyle, and the composition of their gut microbiome. Testing of the gut microbiome plays an important part in this change as it provides data-based insights that can suggest diets for an individual based on their microbial profiles. 
 
The consumers are not only looking for health solutions that are personalized but they are also going to the extent of getting microbiome testing done to have high customized nutrition strategies, which is supporting the process of identifying how different foods interact with gut bacteria, which in turn affects digestion, metabolism, and nutrient absorption. 
 
The capability is so vital that it goes to the very core of individuals dealing with obesity, food allergies, or chronic diseases. Therefore, nutritionists, dietitians, and wellness platforms are all starting to look at microbiome-based nutrition programs with greater interest.

### Advancements in body fat reduction technologies and procedures

The latest generation of non-invasive and minimally invasive devices harness cutting-edge modalities such as high-intensity focused electromagnetic energy (HIFEM), radiofrequency (RF), advanced ultrasound, and combination systems, dramatically improving efficacy and user experience while minimizing recovery times.
 
Notably, FDA-clearance of devices like the Apyx Medical AYON Body Contouring System in 2025 exemplifies these advances, integrating fat extraction, tissue tightening, and electrosurgical features within a single platform designed to streamline multiple treatments in one session, optimizing both time and patient outcomes.
 
Other technologies, such as EmSculpt Neo, leverage dual mechanisms HIFEM contracts muscles times per session, while RF simultaneously heats fat cells. Innovative platforms now combine smart temperature control, AI-driven treatment planning, imaging guidance, and multi-modal energy delivery to enhance precision and safety. 
 
For instance, Alma’s Accent Prime system demonstrated statistically significant reductions in fat layer thickness in a 2025 Korean study and combines ultrasound and RF for greater patient comfort and better results. Furthermore, advances in fractional microneedling RF, high-frequency ultrasound, and injectable lipolysis allow for targeted, customized procedures for anatomically challenging or smaller areas, appealing to a broader patient base.

## Future Outlook

The Gut Microbiome Testing Market size is projected to reach USD 2,104.4 Million by 2035, growing at a CAGR of 7.9%, driven by increasing demand for high-performance computing and enhanced security features.

**New opportunities:**

- Expansion Beyond GI Disorders. Partnerships & Integrated Health Solutions.

## Segment Insights

### By Product & Services: Consumables (largest market) vs Services (fastest growing)

Based on Product and Service, the Gut Microbiome Testing Market has been segmented into Instruments, Consumables and Services. The Services segment held the largest market in 2025, and the 36.8% segment is the fastest growing segment during the forecast period. The Instruments segment in the market comprises sequencing platforms (such as next-generation sequencers), PCR machines, automated sample preparation systems, and other analytical hardware required to perform microbiome analyses. Consumables include reagents, kits for sample collection, DNA/RNA extraction, library preparation, PCR reagents, sequencing reagents, swabs, stabilization vials, cartridges, and other single-use materials required at almost every step of the testing process.

Because consumables are single-use and recurring, they create a robust and predictable revenue stream for suppliers across clinical, research, and direct-to-consumer testing channels. The Services segment in the market includes laboratory testing, bioinformatics analysis, data interpretation and others. For Services, outsourcing remains a cost-effective strategy for many research institutions, hospitals, and small to mid-sized labs that lack the infrastructure or expertise to handle complex microbiome workflows internally. Second, as clinical adoption of microbiome testing expands for example in gastrointestinal disease management, metabolic health monitoring, and drug response prediction demand for specialized interpretation services that comply with regulatory and quality standards will rise.

### By Application: 16S rRNA Sequencing (largest market) vs Shotgun Metagenomics (fastest-growing)

Based on Application, the Gut Microbiome Testing Market has been segmented into 16S rRNA Sequencing, Shotgun Metagenomics, Metatranscriptomics, [Next Generation Sequencing](https://www.marketresearchfuture.com/reports/next-generation-sequencing-market-6354), and Others. The 16S rRNA Sequencing segment held the largest market share of 45% in 2025, while the Shotgun Metagenomics segment is the fastest-growing segment during the forecast period. The 16S rRNA sequencing segment remains one of the most widely adopted technologies in the market due to its cost effectiveness, simplicity, and well-established protocols. It targets the conserved 16S ribosomal RNA gene found in most bacteria and archaea, enabling researchers to profile microbial community composition efficiently, especially for large scale surveys and comparative studies where genus level resolution is sufficient.

Clinicians, research institutions, and many direct-to-consumer gut health services prefer 16S because it delivers reliable taxonomic insights at significantly lower cost and data complexity compared with whole genome approaches, keeping sample processing and analysis workflows streamlined. This depth of analysis is increasingly valuable for advanced clinical research, precision medicine, infectious disease studies, and drug development, where understanding microbial genes, metabolic pathways, and host interactions is essential. The method’s ability to uncover antibiotic resistance genes, virulence factors, and metabolic potentials makes it integral. As precision health initiatives expand globally, shotgun metagenomics is positioned to capture increasing market share.

### By Sample Type: Stool (Fecal) Samples (largest market) vs Saliva Samples (fastest-Growing)

Based on Sample Types, the Gut Microbiome Testing Market has been segmented into Stool (Fecal) Samples, Saliva Samples, Others. Stool (fecal) samples represent the dominant and most clinically relevant sample type in gut microbiome testing today. This is because fecal samples provide the closest and most comprehensive representation of gut microbial composition and function, capturing both microbial diversity and metabolic byproducts. Most validated microbiome testing methods such as 16S rRNA sequencing, shotgun metagenomics, and meta transcriptomics are optimized for stool samples, making them the preferred choice in academic research, pharmaceutical studies, clinical diagnostics, and direct-to-consumer (DTC) gut health testing.

Saliva samples are gaining traction as a non-invasive and easy-to-collect alternative for microbiome testing, particularly in wellness, screening, and large population studies. Although saliva primarily reflects the oral microbiome, it can provide indirect insights into gut health, systemic inflammation, and host–microbe interactions when combined with advanced analytics. The simplicity of saliva collection requiring minimal training, no biohazard handling, and easier shipping makes it attractive for large-scale studies, remote testing programs, and consumer-facing health platforms aiming to reduce barriers to participation, and wellness-oriented applications where ease of collection and participant compliance are prioritized.

### By Indication: Type-2 Diabetes (largest market) vs Obesity(fastest-Growing)

Based on indication, the Gut Microbiome Testing Market has been segmented into Ulcerative Colitis, Irritable Bowel Syndrome (IBS), Chronic Diarrhea & Constipation, Type-2 Diabetes, Obesity, [Rheumatoid Arthritis](https://www.marketresearchfuture.com/reports/rheumatoid-arthritis-market-1658), Multiple Sclerosis, Parkinson’s Disease, Alzheimer’s Disease, and Others. The Irritable Bowel Syndrome (IBS) segment held the largest market share at 25% in 2025, and the Parkinson’s Disease segment is the fastest-growing segment during the forecast period.

Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a strong link to microbial dysbiosis, making microbiome testing increasingly valuable for both research and clinical management. Testing allows researchers and clinicians to monitor microbial composition changes during flare-ups, evaluate patient response to biologic therapies, and identify predictive microbial markers for disease progression. Growth is supported by the rise of biologic and microbiome-targeted therapies, which require companion diagnostics to optimize outcomes. Hospitals and specialized gastroenterology centers are gradually adopting microbiome analysis to supplement traditional invasive diagnostics such as colonoscopy, further solidifying market demand.

### By End User: Diagnostic Laboratories (largest market) vs Hospitals (fastest-Growing)

Based on End User, the Gut Microbiome Testing Market has been segmented into Hospitals, Diagnostic Laboratories, and Others. The Diagnostic Laboratories segment held the largest 55% market share in 2025, and the Hospitals segment is the fastest-growing segment during the forecast period.  Hospitals represent an important but comparatively moderate-share segment in the market. As a result, hospitals tend to rely on external laboratories for sequencing and analysis rather than maintaining full in-house capabilities.

Diagnostic laboratories held the largest market share in 2025, driven by their central role in high-volume sample processing, sequencing, and data interpretation. These labs serve hospitals, research institutions, pharmaceutical companies, and direct-to-consumer (DTC) testing providers, making them the primary commercial hubs of the gut microbiome testing ecosystem. Their ability to invest in advanced sequencing platforms, standardized workflows, and bioinformatics infrastructure allows them to operate at scale.

## Regional Market Share Analysis

### North America**:**Expanding mature ecosystem of biotech

North America is further segmented into the US and Canada. North America benefits from strong venture capital investments, a mature ecosystem of biotech startups, and early regulatory guidance for microbiome diagnostics. North America benefits from strong venture capital investments, a mature ecosystem of biotech startups, and early regulatory guidance for microbiome diagnostics.

Inflammatory bowel disease (IBD) is a group of lifelong diseases affecting the intestines, primarily including ulcerative colitis and Crohn's disease. In the United States, IBD affects an estimated 2.4 to 3.1 million adults, with prevalence rising overall.

Rates are highest among non-Hispanic White populations (0.8%) but are increasing among minority groups, and prevalence rises with age, particularly in adults over 45. Market data confirms that microbiome tests are being developed and used to assess disease risk including for IBD and to guide personalized interventions, expanding demand for gut microbiome analysis.

- According to CDC, inflammatory bowel disease affects approximately 2.4–3.1 million adults in the United States, significantly increasing demand for gut microbiome testing solutions. This growing disease burden supports expansion of precision diagnostics and clinical microbiome applications across healthcare systems.

### Europe: Strong Production high health literacy

Europe is further segmented into Germany, France, UK, Italy, Spain, Russia, and Rest of the Europe. European consumers generally have high health literacy and awareness of the role of gut health in overall well-being. This, combined with strong public investment in digital health and diagnostic innovation, has expanded the market for both clinical microbiome testing and at home testing solutions.

The UK, Germany, and France major European markets show increasing uptake of gut microbiome tests, both for medical insight and broader wellness tracking. Estimated 0.3% of the European population suffers from IBD. Physicians and consumers are increasingly interested in gut microbiome tests to inform IBS, [metabolic syndrome](https://www.marketresearchfuture.com/reports/metabolic-syndrome-market-27832), and other chronic disease management, and to guide lifestyle interventions like diet or nutrition adjustments.

- ECDC reports that inflammatory bowel disease affects about 0.3% of the European population, highlighting rising diagnostic needs across hospitals and laboratories. This supports growth in microbiome-based testing for early detection, disease monitoring, and personalized healthcare interventions.

### Asia Pacific: Fastest Growing rising health awareness

Asia-Pacific is further segmented into the China, India, Japan, South Korea, Malaysia, Thailand, Indonesia, and Rest of Asia-Pacific. The Asia Pacific market is rapidly expanding, supported by large populations, rising health awareness, and increasing prevalence of gastrointestinal disorders. IBS alone affects approximately 6%–10% of the regional population, implying hundreds of millions of potential patients across China, Japan, South Korea, and Southeast Asia, which drives demand for microbiome profiling.

Key regional players include AMILI (Singapore), SpaceGut (Malaysia), Metagen (Japan/Indonesia), Biota Health, and infrastructure leaders like BGI Group (China), offering both clinical and direct-to-consumer testing solutions. Apart from inflammatory bowel disease, metabolic disorders such as Type 2 diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD) are major drivers of gut microbiome testing in Asia Pacific.

### South America: Growing metabolic diseases

South America, high and rising rates of metabolic diseases are creating strong demand for gut microbiome testing because scientific evidence shows that alterations in the gut microbiome are mechanistically linked with obesity, type 2 diabetes (T2DM), and metabolic dysfunction associated fatty liver disease (MAFLD), all of which influence energy regulation, inflammation, and insulin sensitivity.

Metabolic syndrome and obesity are widespread across the region . South America has some of the highest MAFLD prevalence globally, substantially higher than many other regions, and risk factors such as dyslipidemia, hypertension, and T2DM are common in affected populations, creating a substantial comorbidity burden that correlates with gut microbiota changes relevant for testing and stratification.

### Middle East & Africa: Emerging lifestyle changes

Middle East and Africa are further segmented into GCC Countries, South Africa, and Rest of Middle East and Africa. The Gulf Cooperation Council (GCC) countries Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates are experiencing a significant health crisis driven by high rates of chronic metabolic conditions, largely due to rapid urbanization, lifestyle changes, and sedentary behavior. Metabolic syndrome, a cluster of conditions including obesity, high blood pressure, and high blood sugar, affects most of the population in these countries, with rates rising.

The Kingdom's National Biotechnology Strategy aims to position Saudi Arabia as a leading regional biotech hub by 2030 and a global hub by 2040. This strategy is projected to contribute significantly to the non-oil GDP and create jobs by 2030. In 2024, the Saudi government launched the National Biotechnology Strategy, which aims to enhance the country's biotechnology capabilities.

In Africa, research initiatives supported by national foundations and international partners are laying groundwork for microbiome understanding in public health contexts such as infectious disease, malnutrition, and metabolic illness. Although still nascent, centers like the African Centre of Excellence for Genomics of Infectious Diseases (ACEGID) demonstrate the region’s growing genomics research infrastructure.

## Competitive Benchmarking

Many global, regional, and local vendors characterize the Gut Microbiome Testing Market. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth.
 
The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.
 
The major players in the market Include Viome Life Sciences, Inc, Ombre, BaseClear B.v., AtlasBiolabs, Microba Life Sciences, Genova Diagnostics, Inc, Sun Genomics, Inc., BIOHM Health, Inc, Zymo Research Corporation, CosmosID, Inc, strategic market developments and decisions to improve operational effectiveness.

## Recent News & Developments

Viome Life Sciences, Inc, Ombre, BaseClear B.v., AtlasBiolabs, Microba Life Sciences, Genova Diagnostics, Inc, Sun Genomics, Inc., BIOHM Health, Inc, Zymo Research Corporation, CosmosID, Inc.

August 2025: Viome Life Sciences, a mission-driven company that empowers individuals to improve their health, today announced the launch of its new clinically-backed Full Body Intelligence Test, the most advanced holistic health and microbiome-based test ever commercially available.

June 2025: Genova Diagnostics, a global leader in clinical laboratory services, proudly announces the launch of its groundbreaking Alzheimer's Assessment, a non-invasive blood test utilizing the p-Tau217 biomarker for early detection of Alzheimer's disease. This initiative is enabled by a strategic partnership with Neurocode, a leading innovator in neurological diagnostics and research.

September 2025: Biohm Technologies is excited to announce the launch of Phorum, a next-generation postbiotic ingredient designed to support healthy immune function. Developed from heat-treated bacterial and fungal strains, Phorum harnesses the synergy of these microbial components to deliver stable bioactive compounds without requiring live organisms.

## Report Scope

| Market Size 2024 | 914.2 (USD Million) |
| --- | --- |
| Market Size 2025 | 986.42 (USD Million) |
| Market Size 2035 |  2,104.4 (USD Million) |
| Compound Annual Growth Rate (CAGR) | 7.9% (2025 - 2035) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2023 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Viome Life Sciences, Inc, Ombre, BaseClear B.v., AtlasBiolabs, Microba Life Sciences, Genova Diagnostics, Inc, Sun Genomics, Inc., BIOHM Health, Inc, Zymo Research Corporation, CosmosID, Inc. |
| Segments Covered | By Product & Services By Application By Sample Type By Indication By End User |
| Key Market Opportunities | Expansion Beyond GI Disorders Partnerships & Integrated Health Solutions. |
| Key Market Dynamics | Rising Awareness of Gut Health and Disease Linkages Growth of Personalized Nutrition & Preventive Health. |
| Region Covered | North America, Europe, Asia Pacific, South America, Middle East & Africa. |

## Frequently Asked Questions

**Q: How much is the Gut Microbiome Testing Market?**
A: USD 2,104.4 Million (2035)

**Q: What is the growth rate of the Gut Microbiome Testing Market?**
A: 7.9%

**Q: Which region held the largest market share in the Gut Microbiome Testing Market?**
A: Asia Pacific

**Q: Who are the key players in the Gut Microbiome Testing Market?**
A: Viome Life Sciences, Inc, Ombre, BaseClear B.v., AtlasBiolabs, Microba Life Sciences, Genova Diagnostics, Inc, Sun Genomics, Inc., BIOHM Health, Inc, Zymo Research Corporation, CosmosID, Inc.

**Q: Which End User had the largest market share in the Gut Microbiome Testing Market?**
A: Diagnostic Laboratories


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/gut-microbiome-testing-market-68365*